Growth Stocks Worth Watching – June 4th

Prologis, Ascendis Pharma A/S, Teledyne Technologies, Digital Turbine, Hamilton Lane, Pattern Group, and Tyra Biosciences are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of companies expected to grow their earnings, revenue, or market share at a faster rate than the overall market. Investors buy them primarily for their potential for above-average price appreciation, though they may pay little or no dividends and can be more volatile than other stocks. These companies had the highest dollar trading volume of any Growth stocks within the last several days.

Prologis (PLD)

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries.

Read Our Latest Research Report on PLD

Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

Read Our Latest Research Report on ASND

Teledyne Technologies (TDY)

Teledyne Technologies Incorporated, together with its subsidiaries, provides enabling technologies for industrial growth markets in the United States and internationally. Its Digital Imaging segment provides visible spectrum sensors and digital cameras; and infrared, ultraviolet, visible, and X-ray spectra; as well as micro electromechanical systems and semiconductors, including analog-to-digital and digital-to-analog converters.

Read Our Latest Research Report on TDY

Digital Turbine (APPS)

Digital Turbine, Inc., through its subsidiaries, operates a mobile growth platform for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The company operates through two segments, On Device Solutions and App Growth Platform. Its application media platform delivers mobile applications to various publishers, carriers, OEMs, and devices; and content media platform offers news, weather, sports, and other content, as well as programmatic advertising and media content delivery services, and sponsored and editorial content media.

Read Our Latest Research Report on APPS

Hamilton Lane (HLNE)

Hamilton Lane Incorporated is a private equity firm specializing in early venture, emerging growth, turnaround, middle market, mature, mid-venture, bridge, buyout, distressed/vulture, loan, mezzanine in growth capital companies. It prefers to invest in energy, industrials, consumer discretionary, health care, real estate, information technology, utilities, and consumer services.

Read Our Latest Research Report on HLNE

Pattern Group (PTRN)

At Pattern, we are on a mission to help brands accelerate profitable growth on global ecommerce marketplaces. Today, our proprietary technology and on-demand experts operate across more than 60 marketplaces to increase product sales to consumers in more than 100 countries. Utilizing more than 46 trillion data points and sophisticated machine learning and artificial intelligence (“AI”) models, we strive to optimize and automate key levers of ecommerce growth, including advertising, content creation and management, pricing, forecasting and customer service.

Read Our Latest Research Report on PTRN

Tyra Biosciences (TYRA)

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Read Our Latest Research Report on TYRA

Recommended Stories